<DOC>
	<DOCNO>NCT02169713</DOCNO>
	<brief_summary>The purpose study evaluate effect solifenacin mirabegron concentration tamsulosin HCl combine dose . This study also evaluate safety tolerability combine administration solifenacin , mirabegron tamsulosin HCl .</brief_summary>
	<brief_title>Study Evaluate Effect Solifenacin Mirabegron Tamsulosin Hydrochloride ( HCl ) Concentrations Blood Healthy Male Subjects</brief_title>
	<detailed_description>This study comprise two study sequence 2 investigational period sequence . There wash-out period investigational period . Patients admit clinic discharged investigational period .</detailed_description>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Subject body mass index range 18.5 30.0 kg/m2 , inclusive . The subject weigh least 50 kg [ screen ] . Subject female spouse/partners childbearing potential must use highly effective form contraception consist 2 form birth control ( one must barrier method ) start screen continue throughout clinical study period 90 day final study drug administration . Subject must donate sperm start screen throughout clinical study period 90 day final study drug administration . Subject agree participate another interventional study participation present clinical study , define signing informed consent form completion last clinical study visit . Subject know suspected hypersensitivity solifenacin succinate , mirabegron , tamsulosin HCl component formulation use include sulfa allergy . Subject liver function test ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , alkaline phosphatase , gammaglutamyl transferase and/or total bilirubin [ TBL ] ) 1.5 upper limit normal ( ULN ) . In case assessment may repeat [ day1 ] . Subject clinically significant history allergic condition . Subject history evidence clinically significant cardiovascular , gastrointestinal , endocrine , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal and/or major disease malignancy , judge Medical Investigator . Subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior day 2 ( admission day ) . Subject clinically significant abnormality follow Investigator 's review physical examination , electrocardiogram ( ECG ) protocoldefined clinical laboratory test screen day 1 . Subject mean pulse rate &lt; 50 &gt; 90 bpm ; mean systolic BP &lt; 90 mmHg &gt; 140 mmHg ; mean diastolic BP &lt; 60 mmHg &gt; 90 mmHg day 1 ( vital sign measurement take triplicate subject rest supine position 10 min ; pulse rate measure automatically ) . Subject mean QTc ( F ) interval &gt; 430 m ( &gt; 450 subject age 65 ) day 1 . If mean QTc ( F ) exceed limit , 1 additional triplicate ECG take . Subject clinical significant history risk urinary retention , severe gastrointestinal condition ( include toxic megacolon ) , myasthenia gravis narrowangle glaucoma , orthostatic hypotension . Subject history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsade de pointes , structural heart disease , family history Long QT Syndrome . Subject use prescribe nonprescribed drug ( include vitamin , natural herbal remedy [ e.g. , St. John 's Wort ] ) 2 week prior study drug administration , except occasional use paracetamol ( 2 g/day ) . Subject history smoking 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission clinical unit day 2 . Subject history drink 21 unit alcohol per week ( 1 unit = 10 g pure alcohol = 250 mL beer [ 5 % ] 35 mL spirit [ 35 % ] 100 mL wine [ 12 % ] ) within 3 month prior admission clinical unit day 2 . Subject consume grapefruit ( 3 x 200 mL ) marmalade ( 3 time ) , star fruit , Seville oranges Seville orange juicecontaining product week prior admission clinical unit end study visit ( ESV ) , report subject . Subject use drug abuse within 3 month prior admission clinical unit . Subject use inducer metabolism ( e.g. , barbiturate , rifampin ) 3 month prior admission clinical unit regularly . Subject significant blood loss , donate 1 unit ( 500 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinical unit admission day 2 . Subject positive serology test hepatitis B surface antigen , hepatitis B core antibody , hepatitis A virus antibody ( Immunoglobulin M ) , hepatitis C virus antibody human immunodeficiency virus 1 + 2 antibody . Subject participate clinical study treat investigational drug within 28 day prior screen . Subject vulnerable subject ( e.g. , subject kept detention ) . Subject employee Astellas Group Contract Research Organization involve clinical study .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Healthy subject</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Solifenacin</keyword>
	<keyword>Tamsulosin HCl</keyword>
</DOC>